The Challenges

Haematology covers everything from cancers of the blood to bleeding disorders, like haemophilia, and complement system diseases, such as paroxysmal nocturnal haemoglobinuria. Though diverse in nature, what is common across many of these diseases is the serious impact they can have on survival and quality of life. Blood cancers alone are the fourth most common cause of cancer-related death worldwide; the three most common types of blood cancer being myeloma, leukaemia and lymphoma.

Despite considerable progress over the years, many patients still have limited treatment options available to them. To tackle these challenges, we have embarked on journeys of collaboration with academic institutions, regulatory authorities and other companies in the hope of identifying trends or insights from the vast amounts of clinical data across blood diseases, which in turn could lead to future innovations.

Focus

Our commitment extends beyond developing innovative therapies, to playing a wider role in improving patient’s quality of life. We are exploring the best ways to deliver innovations to patients as quickly and effectively as possible, which includes evolving and improving how our clinical trials are designed and how our therapies are administered. We are also looking at new ways to measure treatment success through the use of alternative clinical endpoints.

We continue to invest in bringing innovative treatment options to people with diseases of the blood, as our teams strive to continually deliver transformational change for patients and the physicians who treat them.

Currently, Zentroclox infectious diseases research and development is dedicated to finding effective treatment for a number of life-threatening infections that include viral hepatitis, influenza, multi-drug resistant bacteria, as well as COVID-19 and HIV/AIDs. These diseases, for which there is often a high unmet medical need, affect millions of people worldwide in wide degrees of severity. For this reason, and to ensure each patient receives the most appropriate and effective care, Zentroclox has adopted different strategies to tackle the spread of these infectious diseases – from focusing efforts against multi-drug resistant bacteria into developing treatments for the the top three Gram-negative bacteria identified by the World Health Organization as number one Priority Pathogens, to continuing to innovate treatment solutions to prevent as well as treat influenza, or combining therapies that pair direct-acting antivirals with immune-enhancing molecules to treat viral hepatitis.